Bifosfonati e osteonecrosi dei mascellari (MRONJ)

Quanto se ne scrive

Articoli pubblicati per anno. Nell’ultimo decennio ne sono usciti 1.5× rispetto ai dieci anni precedenti.

Revisioni sistematiche, meta-analisi e consensus

Dove la letteratura tira le somme. Se hai poco tempo, si comincia da qui.

1. 1.
   Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases.

   Ruggiero S, Mehrotra B, Rosenberg TJ, et al. J Oral Maxillofac Surg. 2004;62(5):527-34

   2097 citazioni PubMed 15122554 doi:10.1016/j.joms.2004.02.004

2. 2.
   American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws--2009 update.

   Ruggiero S, Dodson T, Assael L, et al. J Oral Maxillofac Surg. 2009;67(5 Suppl):2-12

   1882 citazioni PubMed 19371809 doi:10.1016/j.joms.2009.01.009

3. 3.
   Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment.

   Marx R, Sawatari Y, Fortin M, et al. J Oral Maxillofac Surg. 2005;63(11):1567-75

   1661 citazioni PubMed 16243172 doi:10.1016/j.joms.2005.07.010

4. 4.
   Diagnosis and Management of Osteonecrosis of the Jaw: A Systematic Review and International Consensus

   Khan AA, Morrison A, Hanley DA, et al. J Bone Miner Res. 2015;30(1):3-23

   1304 citazioni PubMed 25414052 doi:10.1002/jbmr.2405 testo libero

5. 5.
   Systematic Review: Bisphosphonates and Osteonecrosis of the Jaws

   Woo S, Hellstein J, Kalmar J. Annals of Internal Medicine. 2006;144:753-761

   1206 citazioni doi:10.7326/0003-4819-144-10-200605160-00009 testo libero

6. 6.
   American Association of Oral and Maxillofacial Surgeons' Position Paper on Medication-Related Osteonecrosis of the Jaw-2022 Update.

   Ruggiero S, Dodson TB, Aghaloo T, et al. J Oral Maxillofac Surg. 2022;80(5):920-943

   804 citazioni PubMed 35300956 doi:10.1016/j.joms.2022.02.008

7. 7.
   Nature and frequency of bisphosphonate-associated osteonecrosis of the jaws in Australia.

   Mavrokokki T, Cheng A, Stein B, et al. J Oral Maxillofac Surg. 2007;65(3):415-23

   675 citazioni PubMed 17307586 doi:10.1016/j.joms.2006.10.061

8. 8.
   Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases.

   Saad F, Brown JE, Poznak C, et al. Ann Oncol. 2012;23(5):1341-7

   636 citazioni PubMed 21986094 doi:10.1093/annonc/mdr435 testo libero

I lavori più citati di sempre

I riferimenti che tutti gli altri citano. Alcuni hanno trent’anni e restano il fondamento della tecnica.

9. 9.
   Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases.

   Ruggiero S, Mehrotra B, Rosenberg TJ, et al. Journal of oral and maxillofacial surgery. 2004;62(5):527-34

   2097 citazioni PubMed 15122554 doi:10.1016/j.joms.2004.02.004

10. 10.
    American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws--2009 update.

    Ruggiero S, Dodson T, Assael L, et al. Journal of oral and maxillofacial surgery. 2009;67 5 Suppl:2-12

    1882 citazioni PubMed 19371809 doi:10.1016/j.joms.2009.01.009

11. 11.
    Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment.

    Marx R, Sawatari Y, Fortin M, et al. Journal of oral and maxillofacial surgery. 2005;63(11):1567-75

    1661 citazioni PubMed 16243172 doi:10.1016/j.joms.2005.07.010

12. 12.
    Diagnosis and Management of Osteonecrosis of the Jaw: A Systematic Review and International Consensus

    Khan AA, Morrison A, Hanley DA, et al. Journal of Bone and Mineral Research. 2015;30

    1304 citazioni PubMed 25414052 doi:10.1002/jbmr.2405 testo libero

13. 13.
    Systematic Review: Bisphosphonates and Osteonecrosis of the Jaws

    Woo S, Hellstein J, Kalmar J. Annals of Internal Medicine. 2006;144:753-761

    1206 citazioni doi:10.7326/0003-4819-144-10-200605160-00009 testo libero

14. 14.
    Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors.

    Bamias A, Kastritis E, Bamia C, et al. J Clin Oncol. 2005;23(34):8580-7

    1189 citazioni PubMed 16314620 doi:10.1200/jco.2005.02.8670

15. 15.
    American Association of Oral and Maxillofacial Surgeons' Position Paper on Medication-Related Osteonecrosis of the Jaw-2022 Update.

    Ruggiero S, Dodson TB, Aghaloo T, et al. Journal of oral and maxillofacial surgery. 2022

    804 citazioni PubMed 35300956 doi:10.1016/j.joms.2022.02.008

16. 16.
    Nature and frequency of bisphosphonate-associated osteonecrosis of the jaws in Australia.

    Mavrokokki T, Cheng A, Stein B, et al. Journal of oral and maxillofacial surgery. 2007;65(3):415-23

    675 citazioni PubMed 17307586 doi:10.1016/j.joms.2006.10.061

17. 17.
    Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases.

    Saad F, Brown JE, Poznak C, et al. Annals of Oncology. 2012;23(5):1341-7

    636 citazioni PubMed 21986094 doi:10.1093/annonc/mdr435 testo libero

18. 18.
    Osteonecrosis of the jaw in multiple myeloma patients: clinical features and risk factors.

    Badros A, Weikel D, Salama A, et al. J Clin Oncol. 2006;24(6):945-52

    607 citazioni PubMed 16484704 doi:10.1200/jco.2005.04.2465 testo libero

19. 19.
    American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw--2014 update.

    Ruggiero S, Dodson TB, Fantasia J, et al. J Oral Maxillofac Surg. 2014;72(10):1938-56

    606 citazioni PubMed 25234529 doi:10.1016/j.joms.2014.04.031

20. 20.
    Frequency and Risk Factors Associated With Osteonecrosis of the Jaw in Cancer Patients Treated With Intravenous Bisphosphonates

    Hoff A, Toth B, Altundağ K, et al. J Bone Miner Res. 2008;23(6):826-36

    586 citazioni PubMed 18558816 doi:10.1359/jbmr.080205 testo libero

21. 21.
    American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws.

    J Oral Maxillofac Surg. 2007;65(3):369-76

    582 citazioni PubMed 17307580 doi:10.1016/j.joms.2006.11.003

22. 22.
    Bisphosphonate-related osteonecrosis of the jaw: background and guidelines for diagnosis, staging and management.

    Ruggiero S, Fantasia J, Carlson E. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2006;102(4):433-41

    537 citazioni PubMed 16997108 doi:10.1016/j.tripleo.2006.06.004

23. 23.
    Oral bisphosphonate-induced osteonecrosis: risk factors, prediction of risk using serum CTX testing, prevention, and treatment.

    Marx R, Cillo J, Ulloa JJ. J Oral Maxillofac Surg. 2007;65(12):2397-410

    502 citazioni PubMed 18022461 doi:10.1016/j.joms.2007.08.003

24. 24.
    The pathogenesis of bisphosphonate-related osteonecrosis of the jaw: so many hypotheses, so few data.

    Allen M, Burr D. J Oral Maxillofac Surg. 2009;67(5 Suppl):61-70

    462 citazioni PubMed 19371816 doi:10.1016/j.joms.2009.01.007 testo libero

25. 25.
    Longitudinal cohort study of risk factors in cancer patients of bisphosphonate-related osteonecrosis of the jaw.

    Vahtsevanos K, Kyrgidis A, Verrou E, et al. J Clin Oncol. 2009;27(32):5356-62

    455 citazioni PubMed 19805682 doi:10.1200/jco.2009.21.9584

26. 26.
    Decreased occurrence of osteonecrosis of the jaw after implementation of dental preventive measures in solid tumour patients with bone metastases treated with bisphosphonates. The experience of the National Cancer Institute of Milan.

    Ripamonti C, Maniezzo M, Campa T, et al. Ann Oncol. 2009;20(1):137-45

    442 citazioni PubMed 18647964 doi:10.1093/annonc/mdn526 testo libero

27. 27.
    Reduction of osteonecrosis of the jaw (ONJ) after implementation of preventive measures in patients with multiple myeloma treated with zoledronic acid.

    Dimopoulos M, Kastritis E, Bamia C, et al. Ann Oncol. 2009;20(1):117-20

    440 citazioni PubMed 18689864 doi:10.1093/annonc/mdn554 testo libero

28. 28.
    Practical guidelines for the prevention, diagnosis, and treatment of osteonecrosis of the jaw in patients with cancer.

    Ruggiero S, Gralow J, Marx R, et al. J Oncol Pract. 2006;2(1):7-14

    376 citazioni PubMed 20871729 doi:10.1200/jop.2.1.7 testo libero

Gli ultimi tre anni

Cosa è uscito di recente, ordinato per quanto è già stato citato.

29. 29.
    Italian position paper (SIPMO‐SICMF) on medication‐related osteonecrosis of the jaw (MRONJ)

    Bedogni A, Mauceri R, Fusco V, et al. Oral Dis. 2024;30(6):3679-3709

    119 citazioni PubMed 38317291 doi:10.1111/odi.14887 testo libero

30. 30.
    Functionalized DNA Nanomaterials Targeting Toll‐Like Receptor 4 Prevent Bisphosphonate‐Related Osteonecrosis of the Jaw via Regulating Mitochondrial Homeostasis in Macrophages

    Tao Z, Ma H, Zhang X, et al. Advanced Functional Materials. 2023;33

    75 citazioni doi:10.1002/adfm.202213401

31. 31.
    Pathophysiology of Medication‐Related Osteonecrosis of the Jaw—A Minireview

    Tetradis S, Allen M, Ruggiero S. JBMR Plus. 2023;7(8):e10785

    60 citazioni PubMed 37614299 doi:10.1002/jbm4.10785 testo libero

32. 32.
    Medication-induced osteonecrosis of the jaw: a review of cases from the Food and Drug Administration Adverse Event Reporting System (FAERS)

    Ahdi HS, Wichelmann T, Pandravada S, et al. BMC Pharmacol Toxicol. 2023;24(1):15

    59 citazioni PubMed 36879299 doi:10.1186/s40360-023-00657-y testo libero

33. 33.
    Risk of medication-related osteonecrosis of the jaw after dental extractions in patients receiving antiresorptive agents - A retrospective study of 240 patients.

    Coropciuc R, Coopman R, Garip M, et al. Bone. 2023;170:116722

    42 citazioni PubMed 36858337 doi:10.1016/j.bone.2023.116722 testo libero

34. 34.
    Osteonecrosis of the Jaw

    Brzak BL, Aleksijević LH, Vindiš E, et al. Dent J (Basel). 2023;11(1)

    39 citazioni PubMed 36661560 doi:10.3390/dj11010023 testo libero

35. 35.
    Risk comparison of osteonecrosis of the jaw in osteoporotic patients treated with bisphosphonates vs. denosumab: a multi-institutional retrospective cohort study in Taiwan

    Liu F, Luk K, Chen Y. Osteoporos Int. 2023;34(10):1729-1737

    37 citazioni PubMed 37326685 doi:10.1007/s00198-023-06818-3 testo libero

36. 36.
    Bisphosphonates and Their Connection to Dental Procedures: Exploring Bisphosphonate-Related Osteonecrosis of the Jaws

    Lee ES, Tsai M, Lee J, et al. Cancers (Basel). 2023;15(22)

    34 citazioni PubMed 38001626 doi:10.3390/cancers15225366 testo libero

37. 37.
    Low-level laser therapy prevents medication-related osteonecrosis of the jaw-like lesions via IL-1RA-mediated primary gingival wound healing

    Zheng Y, Dong X, Chen S, et al. BMC Oral Health. 2023;23(1):14

    34 citazioni PubMed 36627695 doi:10.1186/s12903-022-02678-1 testo libero

38. 38.
    Bisphosphonate-Related Osteonecrosis of the Jaw and Oral Microbiome: Clinical Risk Factors, Pathophysiology and Treatment Options

    Jelin-Uhlig S, Weigel M, Ott B, et al. Int J Mol Sci. 2024;25(15)

    33 citazioni PubMed 39125621 doi:10.3390/ijms25158053 testo libero